Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui Public Health Clinical Center, Hefei, China.
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui Public Health Clinical Center, 100 Huaihai Road, Hefei 230012, China;, Email:
Pharmazie. 2023 Apr 15;78(1):13-16. doi: 10.1691/ph.2023.2536.
The present study aimed to investigate the efficacy and safety of flumatinib in patients newly diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP). A retrospective study was conducted using five patients newly diagnosed with CML-CP who received flumatinib (600 mg/day). Results of the present study demonstrated that all five patients with CML-CP that were treated with flumatinib achieved the optimal molecular response within three months. In addition, two patients experienced major molecular response (MMR), and one patient acquired undetectable molecular residual disease, which was maintained for more than one year. Moreover, one patient exhibited grade 3 hematological toxicity, two patients exhibited transient diarrhea, one patient exhibited vomiting and one patient exhibited a rash with pruritus. No second-generation tyrosine kinase inhibitor-specific adverse cardiovascular events occurred in any patients. In conclusion, flumatinib exhibits high efficacy and high early molecular response rate in patients newly diagnosed with CML-CP. The majority of patients obtained MMR within three months, and the adverse reactions experienced were mild and tolerable.
本研究旨在探讨氟马替尼在初诊慢性髓性白血病慢性期（CML-CP）患者中的疗效和安全性。采用回顾性研究方法，纳入 5 例初诊 CML-CP 患者接受氟马替尼（600mg/天）治疗。本研究结果显示，所有 5 例接受氟马替尼治疗的 CML-CP 患者均在 3 个月内达到最佳分子学反应。此外，2 例患者获得主要分子学反应（MMR），1 例患者获得不可检测的分子残留病，且持续超过 1 年。此外，1 例患者出现 3 级血液学毒性，2 例患者出现短暂性腹泻，1 例患者出现呕吐，1 例患者出现伴有瘙痒的皮疹。未发生任何患者第二代酪氨酸激酶抑制剂特有的心血管不良事件。总之，氟马替尼在初诊 CML-CP 患者中表现出较高的疗效和较高的早期分子学反应率。大多数患者在 3 个月内获得 MMR，且不良反应轻微且可耐受。
Zotero 插件